Drug Discovery

A new computational tool could help improve the stability and predictability of ADCs.

With many cell and gene therapies skipping phase III trials entirely, academics must get to grips with GMP early.

Miguel Forte argues it’s time to fine tune the way we target solid tumors...

"Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity."

How can wood be used to produce pharmaceutically relevant compounds?

A three-in-one approach to drug delivery combines different actives in a hydrogel-based delivery method.

Will unlocking the secrets of the microbiome yield a promising new horizon for medicine?

Industry experts share how their therapeutic products are shaping the future of the pharmaceutical landscape.

Some have dismissed excitement about the microbiome as “hype,” but real results are beginning to be seen.

David Donabedian of Axial Biotherapuetics explains the role of the microbiome in the onset of Parkinson's Disease and autism.